// App-Quantinova.ai

S130 : SEQUENTIAL NCRI AML TRIALS SHOW CONSISTENT BENEFIT FOR RIC TRANSPLANT IN CR1 FOR OLDER PATIENTS >60YEARS THAT IS INDEPENDENT OF MRD STATUS AFTER FIRST INDUCTION

Researchers

Presenter

  • Nigel Russell

Principal Investigators

  • Abin Thomas

  • Robert Hills

  • Rebecca Wilson

  • Ian Thomas

  • Asim Khwaja

  • Matthew Smith

  • Duruta Weber

  • Alan Burnett

  • Mike Dennis

  • Steve Knapper

  • Sylvie Freeman

Medical Centers

  • Rheumatology, Guy's Hospital, London, United Kingdom

  • Odense University Hospital, Odense, Denmark

  • Nuffield Department of Population Health HSRU, University of Oxford, Oxford, United Kingdom

  • Centre for Trials Research, Cardiff University, Cardiff, United Kingdom

  • Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom

  • Centre for Trials Research, Cardiff University, Cardiff, United Kingdom

  • Histopathology, Barts Health NHS Trust, London, United Kingdom

  • Cancer Institute,University College Hospital NHS Foundation Trust,London,United Kingdom

  • Haematology, Christie NHS Foundation Trust, Manchester, United Kingdom

  • Cardiff and Vale University Health Board, Cardiff,

  • Blackwatergate,Arran,United Kingdom

Locations

  • United Kingdom

  • Denmark

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Daunorubicin

  • Clofarabine

  • Cladribine

  • Gemtuzumab ozogamicin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved